NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69–GeparSepto | Journal of Clinical Oncology
Randomized phase II study of nab‐paclitaxel as first‐line chemotherapy in patients with HER2‐negative metastatic breast cancer - Tamura - 2017 - Cancer Science - Wiley Online Library
Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial - eClinicalMedicine
Nab-Paclitaxel: A New Standard of Care in Neoadjuvant Therapy of High-Risk Early Breast Cancer? | Journal of Clinical Oncology
Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: A post-hoc analysis - ScienceDirect
Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial - The Lancet Healthy Longevity
Counteracting gemcitabine+nab-paclitaxel induced dysbiosis in KRAS wild type and KRASG12D mutated pancreatic cancer in vivo model | Cell Death Discovery
NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69–GeparSepto | Journal of Clinical Oncology
Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer | npj Breast Cancer
Dosing Modifications of nab-Paclitaxel Therapy by Age | Download Scientific Diagram
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine | NEJM
Advantages with Nab-Paclitaxel in TNBC
A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01) | BMC Cancer | Full Text
Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial - eClinicalMedicine
Nab-Paclitaxel: A New Standard of Care in Neoadjuvant Therapy of High-Risk Early Breast Cancer? | Journal of Clinical Oncology
A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer - ScienceDirect
Nab-paclitaxel regimen active in locally advanced cervical cancer
Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma | British Journal of Cancer
PD Dr. med. Oleg Gluz on LinkedIn: Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed…
Dose Delivery Nab-Paclitaxel Carboplatin | Download Scientific Diagram
gynonko-express
Frontiers | Efficacy and Safety of Albumin-Bound Paclitaxel Compared to Docetaxel as Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer
Biomedicines | Free Full-Text | Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety
